Fierce Biotech
Recent coverage
Front-page news, podcasts and videos about Fierce Biotech
Neoleukin Therapeutics Cuts 70% of Workforce, CEO Jonathan Drachman to Step Down Amid Strategic Review
Neoleukin Therapeutics is cutting about 70% of its workforce and exploring strategic alternatives including sale or merger, with CEO Jonathan Drachman stepping down. The company’s stock rose by over 30% following the announcement.
Century Therapeutics Cuts 25% Staff, Closes Seattle and Hamilton Sites, R&D Head Hyam Levitsky to Resign by Jan 31
Century Therapeutics is closing its Seattle hub and cutting 25% of its workforce, including a shutdown of its Hamilton, Ontario location, as it shifts priorities and extends its cash runway to 2026. The company’s president of R&D, Hyam Levitsky, plans to resign by January 31, and Century is de-prioritizing programs for glioblastoma and blood cancers.
By Fierce Biotech
BrainChild Bio raises $116M Series A from Seattle Children’s and WRF to fund pivotal CAR-T trial for DIPG
BrainChild Bio, spun out of Seattle Children’s Hospital, raised $116 million in a Series A led by Seattle Children’s and WRF Capital to fund a pivotal phase 2 trial of CAR-T candidate BCB-276 for diffuse intrinsic pontine glioma (DIPG) and advance a planned phase 1 glioblastoma program.
